{
    "root": "a12b8b2c-799f-4090-81be-340ac97c6920",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250314",
    "ingredients": [
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM CARBONATE DECAHYDRATE",
            "code": "LS505BG22I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "CI 77891",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "pantoprazole proton pump inhibitor ( ppi ) indicated following : short-term treatment erosive esophagitis associated gastroesophageal reflux disease ( gerd ) ( 1.1 ) maintenance healing erosive esophagitis ( 1.2 ) pathological hypersecretory conditions including zollinger-ellison ( ze ) syndrome ( 1.3 )",
    "contraindications": "indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 wks children ( 5 years older ) ≥ 15 kg < 40 kg 20 mg daily 8 wks ≥ 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily * pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily * controlled extend beyond 12 months full prescribing information instructions",
    "warningsAndPrecautions": "product : 50090-7512 ndc : 50090-7512-1 12960 tablet , delayed release case ndc : 50090-7512-0 90 tablet , delayed release bottle",
    "adverseReactions": "pantoprazole sodium contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE)  Syndrome ( 1.3 )",
    "contraindications_original": "Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily * Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions",
    "warningsAndPrecautions_original": "Product:    50090-7512\n                  NDC:    50090-7512-1   12960 TABLET, DELAYED RELEASE in a CASE\n                  NDC:    50090-7512-0   90 TABLET, DELAYED RELEASE in a BOTTLE",
    "adverseReactions_original": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6)].\n                  \n                  \n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}